A series of tetrahydrocarbazole derivatives was designed and synthesized on the basis of the AMP-activated protein kinase activator GY3. All the synthesized compounds were screened in HepG2 cell lines for glucose consumption activity and several of them showed potent glucose decreasing activity. In vivo evaluation of the hypoglycemic and hypolipemic effects indicated that 7a exhibited comparable activity with pioglitazone, but with a weaker body-weight increasing effect. The pharmacokinetic profiles of 7a were also investigated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2018.02.069 | DOI Listing |
Publication Analysis
Top Keywords
hypoglycemic hypolipemic
8
discovery tetrahydrocarbazoles
4
tetrahydrocarbazoles potent
4
potent hypoglycemic
4
hypolipemic activities
4
activities series
4
series tetrahydrocarbazole
4
tetrahydrocarbazole derivatives
4
derivatives designed
4
designed synthesized
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!